References

1 Min B, Prout M, Hu-Li J, Zhu J, Jankovic D, Morgan ES, Urban JF Jr, Dvorak AM, Finkelman FD, LeGros G, Paul WE: Basophils produce IL-4 and accumulate in tissues after infection with a Th2-inducing parasite. J Exp Med 2004;200:507–517.

2 Ohnmacht C, Voehringer D: Basophil effector function and homeostasis during helminth infection. Blood 2009;113:2816–2825.

3 Mukai K, Matsuoka K, Taya C, Suzuki H, Yokozeki H, Nishioka K, Hirokawa K, Etori M, Yamashita M, Kubota T, Minegishi Y, Yonekawa H, Karasuyama H: Basophils play a critical role in the development of IgE-mediated chronic allergic inflammation independently of T cells and mast cells. Immunity 2005;23:191–202.

4 Khodoun MV, Orekhova T, Potter C, Morris S, Finkelman FD: Basophils initiate IL-4 production during a memory T-dependent response. J Exp Med 2004;200:857–870.

5 Tsujimura Y, Obata K, Mukai K, Shindou H, Yoshida M, Nishikado H, Kawano Y, Minegishi Y, Shimizu T, Karasuyama H: Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis. Immunity 2008; 28:581–589.

6 Denzel A, Maus UA, Rodriguez Gomez M, Moll C, Niedermeier M, Winter C, Maus R, Hollingshead S, Briles DE, Kunz-Schughart LA, Talke Y, Mack M: Basophils enhance immunological memory responses. Nat Immunol 2008;9:733–742.

7 Visness CM, London SJ, Daniels JL, Kaufman JS, Yeatts KB, Siega-Riz AM, Liu AH, Calatroni A, Zeldin DC: Association of obesity with IgE levels and allergy symptoms in children and adolescents: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2009;123:1163–1169.

8 Al-Shawwa BA, Al-Huniti NH, DeMattia L, Gershan W: Asthma and insulin resistance in morbidly obese children and adolescents. J Asthma 2007;44:469–473.

9 Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D'Agati V, Schmidt AM: Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003;14: 1383–1395.

10 Yan SF, Ramasamy R, Schmidt AM: The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010;106:842–853.

11 Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, Rieber EP: Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res 2006;323:475–488.

12 Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A, Nakae S, Matsushima K, Ohta K, Yamamoto K, Yamaguchi M: An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol 2008;181:5981–5989.

13 Yoshimura-Uchiyama C, Yamaguchi M, Nagase H, Fujisawa T, Ra C, Matsushima K, Iwata T, Igarashi T, Yamamoto K, Hirai K: Comparative effects of basophil-directed growth factors. Biochem Biophys Res Commun 2003;302:201–206.

14 Iikura M, Yamaguchi M, Fujisawa T, Miyamasu M, Takaishi T, Morita Y, Iwase T, Moro I, Yamamoto K, Hirai K: Secretory IgA induces degranulation of IL-3-primed basophils. J Immunol 1998;161:1510–1515.

15 Yoshimaru T, Suzuki Y, Inoue T, Nishida S, Ra C: Extracellular superoxide released from mitochondria mediates mast cell death by advanced glycation end products. Biochim Biophys Acta 2008;1783:2332–2343.

16 Sick E, Brehin S, Andre P, Coupin G, Landry Y, Takeda K, Gies JP: Advanced glycation end products (ages) activate mast cells. Br J Pharmacol 2010;161:442–455.

17 Hirai K, Miyamasu M, Takaishi T, Morita Y: Regulation of the function of eosinophils and basophils. Crit Rev Immunol 1997;17: 325–352.

18 Bochner BS, McKelvey AA, Sterbinsky SA, Hildreth JE, Derse CP, Klunk DA, Lichtenstein LM, Schleimer RP: IL-3 augments adhesiveness for endothelium and CD11b expression in human basophils but not neutrophils. J Immunol 1990;145:1832–1837.

19 Gottsater A, Szelag B, Kangro M, Wroblewski M, Sundkvist G: Plasma adiponectin and serum advanced glycated end-products increase and plasma lipid concentrations decrease with increasing duration of type 2 diabetes. Eur J Endocrinol 2004;151:361–366.

20 Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992;267:5133–5138.

21 Liu Y, Liang C, Liu X, Liao B, Pan X, Ren Y, Fan M, Li M, He Z, Wu J, Wu Z: AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kappaB pathways. Atherosclerosis 2010;208:34–42.

22 Sun C, Liang C, Ren Y, Zhen Y, He Z, Wang H, Tan H, Pan X, Wu Z: Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol 2009;104:42–49.

23 Vlassara H: The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001;17:436–443.

24 Horiuchi S, Higashi T, Ikeda K, Saishoji T, Jinnouchi Y, Sano H, Shibayama R, Sakamoto T, Araki N: Advanced glycation end products and their recognition by macrophage and macrophage-derived cells. Diabetes 1996;45(suppl 3):S73–S76.

25 Peleg AY, Weerarathna T, McCarthy JS, Davis TM: Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007;23:3–13.

26 Joshi N, Caputo GM, Weitekamp MR, Karchmer AW: Infections in patients with diabetes mellitus. N Engl J Med 1999;341: 1906–1912.

27 Otton R, Soriano FG, Verlengia R, Curi R: Diabetes induces apoptosis in lymphocytes. J Endocrinol 2004;182:145–156.

28 Tedgui A, Mallat Z: Apoptosis as a determinant of atherothrombosis. Thromb Haemost 2001;86:420–426.

29 Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M, Dombret MC, Sims GP, Kolbeck R, Coyle AJ, Aubier M, Pretolani M: Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:917–927.

30 Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M: The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 2006;19:1437–1445.

Han/Suzukawa/Yamaguchi/Sugimoto/
Nakase/Toda/Nagase/Ohta

Leptin Enhances Survival and Induces Migration, Degranulation, and Cytokine Synthesis of Human Basophils

Maho Suzukawa,* Hiroyuki Nagase,* Ikuko Ogahara,* Kaiyu Han,* Hiroyuki Tashimo,* Akiko Shibui,[†] Rikiya Koketsu,*,[‡] Susumu Nakae,[§] Masao Yamaguchi,* and Ken Ohta*

Basophils are the rarest leukocytes in human blood, but they are now recognized as one of the most important immunomodulatory as well as effector cells in allergic inflammation. Leptin, a member of the IL-6 cytokine family, has metabolic effects as an adipokine, and it is also known to participate in the pathogenesis of inflammatory reactions. Because there is an epidemiologic relationship between obesity and allergy, we examined whether basophil functions are modified by leptin. We found that human basophils express leptin receptor (LepR) at both the mRNA and surface protein levels, which were upregulated by IL-33. Leptin exerted strong effects on multiple basophil functions. It induced a strong migratory response in human basophils, similar in potency to that of basophil-active chemokines. Also, leptin enhanced survival of human basophils, although its potency was less than that of IL-3. Additionally, CD63, a basophil activation marker expressed on the cell surface, was upregulated by leptin, an effect that was neutralized by blocking of LepR. Assessments of basophil degranulation and cytokine synthesis found that leptin showed a strong priming effect on human basophil degranulation in response to FcεRI aggregation and induced Th2, but not Th1, cytokine production by the cells. In summary, the present findings indicate that leptin may be a key molecule mediating the effects of adipocytes on inflammatory cells such as basophils by binding to LepR and activating the cellular functions, presumably exacerbating allergic inflammation. *The Journal of Immunology*, 2011, 186: 5254–5260.

Basophils are the least common circulating leukocytes in human blood. They possess FcεRI, a high-affinity receptor for IgE, abundantly on their surface and, following cross-linkage of IgE on their surface by specific Ags, they degranulate and release chemical mediators such as histamine from their cytoplasmic granules. These cells have long been thought to behave as effector cells in allergic inflammation, since influx of basophils is observed in the upper and lower airways hours after Ag challenge (1, 2). However, new evidence obtained from murine studies clearly revealed that the role of basophils is not restricted to local effector actions, but extends to regulation and modulation of allergic inflammation. These newly uncovered aspects of basophils include initiation of Th2 responses after Ag challenge (3) and regulation of immunological memory (4). As a result, basophils are now increasingly recognized as important immunomodulatory cells in allergic diseases that are attracted to, and activated at, allergic inflammatory sites (5).

We and others have previously reported that several cytokines regulate basophil functions. IL-3, IL-5, and GM-CSF are well-known basophil activators (6–8), and we very recently demonstrated that IL-33 potently activates human basophils directly and also primes them (9). In addition to these cytokines, chemical substances such as fMLP and lipid mediators also possess the ability to modify and regulate basophil functions (10). A better understanding of the precise mechanisms of basophil activation is important for clarifying the pathogenesis of allergic diseases, and it will also potentially lead to the development of new and better therapeutic strategies because basophils are one of the key cell types that potently regulate allergic inflammation.

Today, the incidences of allergic diseases as well as obesity are rapidly increasing, especially in industrialized countries. Obesity is closely related to asthma and airway hyperresponsiveness (11, 12), and the relative risk of asthma rises with increasing obesity. Several clinical observations suggest that obesity worsens asthma control and that asthma in obese subjects has distinct features compared with the disease in nonobese subjects. These observations are that obese asthmatics tend to have a more severe form of asthma (13), respond less well to standard asthma therapy (14), and show resistance to glucocorticoid therapy (15). In fact, weight reduction in obese patients with asthma results in improvement in the asthma severity and symptoms (16). Also, in an animal model, airway responsiveness was shown to be increased in genetically obese mice (17). Based on these observations, obesity and asthma are thought to have a close relationship and there is an urgent need to clarify the precise mechanisms that account for the mutual interaction between these disorders.

In obese subjects, adipocytes secrete increased amounts of adipokines, a series of mediators showing significant metabolic effects. It was recently suggested that some adipokines may also be

*Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo 173-8605, Japan; [†]Department of Medical Genomics, Graduate School of Frontier Sciences, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; [‡]Department of Allergy and Rheumatology, University of Tokyo Graduate School of Medicine, Tokyo 113-0033, Japan; and [§]Frontier Research Initiative, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan

Address correspondence and reprint requests to Dr. Maho Suzukawa, Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan. E-mail address: fueta-tky@umin.ac.jp

Abbreviations used in this article: Ct, threshold cycle; LepR, leptin receptor; MESF, molecules of equivalent soluble fluorochrome units; RQ, relative quantitation.

involved in allergic inflammation through modification of immunological responses (18). These adipokines include leptin, a 16-kDa hormone synthesized mainly by adipocytes. Leptin was originally identified as the gene defect responsible for the obese phenotype in ob/ob mice (19), and it is a member of the IL-6 family of cytokines, which have strong structural similarities with G-CSF (20). Leptin receptor (LepR) is a member of the class I cytokine receptor family and, due to alternative splicing, it has six isoforms (LepRa through LepRf). They differ in the length of their intracellular domain, and the long full-length isoform (LepRb) is the receptor responsible for most of the known effects of leptin. These leptin receptors are expressed in various organs, including the lung, kidney, adrenal gland, hematopoietic cells, and bone marrow (21). Also, cells such as neutrophils, monocytes, T cells, and eosinophils have been shown to express functional leptin receptors (22–24), but it has been unclear whether basophils also possess leptin receptors.

On the basis of this background, we conducted analyses to elucidate the effects of this obesity-related mediator, leptin, on human basophil activation. In this study, we report for the first time, to our knowledge, that human basophils express receptors for leptin, and that leptin potently affects basophil migration, survival, CD63 expression, degranulation, and Th2 cytokine synthesis.

Materials and Methods

Reagents

The following reagents were purchased as indicated: human recombinant leptin, human eotaxin/CCL11, and RANTES/CCL5 (R&D Systems, Minneapolis, MN); human MCP-1/CCL2 and IL-3 (PeproTech, Rocky Hill, NJ); human IL-33 (Adipogen, Incheon, South Korea); Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden); PBS and RPMI 1640 medium (Life Technologies, Grand Island, NY); and PIPES (Sigma-Aldrich, St. Louis, MO).

The following Abs were purchased as indicated: mouse anti-leptin mAb (IgG1, clone 44802), mouse IgG1 with irrelevant specificity, normal goat IgG, CFS-conjugated mouse anti-leptin receptor mAb (IgG2b, clone 52263), and CFS-conjugated mouse IgG2b (R&D Systems); goat anti-LepR (Santa Cruz Biotechnology, Santa Cruz, CA); PE-conjugated mouse anti-CD63 (IgG1, clone H5C6) (BD Biosciences, San Jose, CA); PE-conjugated mouse IgG1 and PE-conjugated anti-CD11b mAb (mouse IgG1, clone Bear1) (Coulter Immunotech, Marseille, France); and goat anti-human IgE Ab and FITC-conjugated goat anti-human IgE Ab (Biosource International, Camarillo, CA). Mouse anti-human FcεRI α-chain mAb CRA-1 was provided by Dr. Chisei Ra of Nihon University.

Cell preparation

Leukocytes were isolated from venous blood obtained from consenting volunteers. PBMCs were obtained by the standard density gradient technique (25).

Basophils were semipurified by density centrifugation using Percoll solutions of two different densities (1.080 and 1.070 g/ml), as previously described (9). The purity of these Percoll-separated basophil preparations was usually 5–15%, and the yield was ~0.5–1.0 × 10^5 basophils/ml of peripheral blood. For some experiments, Percoll-separated basophils were further purified by negative selection with MACS beads (basophil isolation kit; Miltenyi Biotec, Belgisch-Gladbach, Germany) according to the manufacturer's instructions (purity, 97–100%).

Eosinophils were purified by density gradient centrifugation followed by negative selection using anti–CD16-bound beads as previously described (25) (purity, 97–100%).

Human neutrophils were separated by density gradient centrifugation followed by negative selection using anti–CD14-bound micromagnetic beads (Miltenyi Biotec) (purity, 97–99%).

Real-time quantitative PCR analysis for LepR

Real-time quantitative PCR analysis was performed using a LightCycler Fast Start DNA Master SYBR Green I kit and LightCycler Fast Start DNA Master HybProbe (Roche Diagnostics, Mannheim, Germany). In brief, total RNA was extracted from highly purified cell preparations from separate donors using an RNeasy Mini kit (Qiagen, Hilden, Germany). Real-time PCR was performed using a LightCycler (Roche Diagnostics). The primers, probes, and standards were designed by Nihon Gene Research Laboratory (Sendai, Japan). Data were calculated as the ratios of the quantities of measured mRNA to β-actin mRNA.

Flow cytometric analysis of surface-expressed molecules

LepR expression in highly purified basophils was analyzed by flow cytometry. MACS-separated basophils were incubated with CFS-conjugated mouse anti-LepR mAb or control CFS-conjugated mouse IgG2b and then analyzed with a FACSCalibur (BD Biosciences, Franklin Lakes, NJ). For some experiments, highly purified basophils were incubated with stimulants in RPMI 1640 medium supplemented with 10% FCS, and after 24 h, cells were stained and analyzed by flow cytometry.

CD63 and CD11b expression levels were analyzed using semipurified basophils. Following stimulation in PIPES buffer containing 25 mM PIPES, 119 mM NaCl, 5 mM KCl, 2 mM Ca^{2+}, 0.5 mM Mg^{2+}, and 0.03% human serum albumin for 60 min, basophils were incubated with either PE-conjugated anti-CD63 mAb, PE-conjugated anti-CD11b, or PE-conjugated control mouse IgG1 and then stained with FITC-conjugated anti-human IgE Ab at 10 μg/ml. Cells showing strong positive staining for IgE were considered to be basophils and were further analyzed for their PE fluorescence. The median values of fluorescence intensity for the basophils were converted to the numbers of molecules of equivalent soluble fluorochrome units (MESF), as previously described (26). Surface expression levels were semiquantified using the following formula: ΔMESF = (MESF of cells stained with specific mAb) − (MESF of cells stained with control IgG).

Chemotaxis assay

Basophil chemotaxis experiments were performed using Chemotaxicell (Kurabo, Osaka, Japan) as previously described (26). Migration was expressed as a percentage of the inoculated cells.

Survival assay

Highly purified basophils were cultured in RPMI 1640 medium supplemented with 10% FCS, 100 U/ml penicillin, and 100 μg/ml streptomycin (Sigma-Aldrich). Differential analysis of apoptotic and live cells was performed using a MEBCYTO apoptosis kit (MBL, Nagoya, Japan) and flow cytometry as previously described (27).

Degranulation of human basophils

Basophil degranulation was examined by measuring the supernatant histamine content using semipurified basophils, as previously described (28).

Quantification of basophil-derived cytokines

Highly purified basophils at a cell density of 1 × 10^6 cells/ml were cultured with cytokines in RPMI 1640 medium containing 10% FCS overnight at 37°C, and the supernatant was stored at −80°C until assay. Also, the cell fractions were lysed in ISOGEN (Nippon Gene, Tokyo, Japan), and the total RNA was extracted according to the manufacturer's instructions. Human IL-4 was measured using the Quantikine HS human IL-4 immunoassay (R&D Systems), human IL-13 was measured using an IL-13 ELISA kit (Thermo Fisher Scientific, Rockford, IL), and human leptin was measured using a human leptin immunoassay kit (Invitrogen, Carlsbad, CA). The mRNA expression was analyzed using an Applied Biosystems 7500 real-time PCR system (PE Applied Biosystems, Foster City, CA). The primers and probes for human β-actin, IL-4, IL-13, and leptin were designed by PE Applied Biosystems. For each sample, the differences in threshold cycles (Cts) between the cytokine and β-actin genes (ΔCt$_{sample}$, ΔCt$_{control}$) were determined, and a calibrated ΔCt value (ΔΔCt, ΔCt$_{sample}$ − ΔCt$_{control}$) was calculated. Then, the relative quantitation (RQ) values were calculated using the following equation: RQ = 2$^{-ΔΔCt}$.

Statistics

All data are expressed as the mean ± SEM. Differences between values were analyzed by a Student t test.

Results

Human basophils express LepR

In the first series of experiments, we studied the expression of mRNA for the leptin receptor, LepR, in highly purified human basophils, neutrophils, eosinophils, and PBMCs by quantifying the

expression levels of transcripts for LepR by real-time PCR (Fig. 1A). Basophils expressed LepR mRNA at a level similar to other granulocytes but lower than the level expressed by PBMCs. We also examined basophil surface expression of LepR by flow cytometry. As shown in Fig. 1B, LepR was expressed on the surface of basophils. We next stimulated basophils with potent stimuli, that is, IL-3, IgE aggregation, and IL-33 (9), to see whether they affected the expression level of LepR. Interestingly, basophils stimulated with IL-33 at 100 ng/ml expressed higher levels of LepR, as shown in Fig. 1C, whereas basophils stimulated with IL-3 at 300 pM or CRA-1 mAb at 100 ng/ml showed no change in the LepR expression level (data not shown). These results indicate that basophils express LepR at both the mRNA and surface protein levels, and that these expression levels are affected by IL-33. In the following experiments using leptin, we assessed whether LepR expressed on basophils was functional.

Leptin induces migration of human basophils

It has been demonstrated that in vivo administration of leptin attracts inflammatory cells to the sites of allergic inflammation (29). Basophils potentially play a role in allergic inflammation, and for that reason we investigated whether leptin regulates human basophil migration. We found that leptin added to the lower chambers of Chemotaxicell induced dose-dependent migration of human basophils (Fig. 2A), showing the strongest effect at a concentration of 3 μM. It is noteworthy that the maximal effect of leptin on human basophil migration was as strong as the effects of several well-known chemokines, including eotaxin, MCP-1, and RANTES. Also, when added together with cells to the upper chambers of Chemotaxicell, leptin at 1–10 μM enhanced basophil migration toward eotaxin (10 nM) (Fig. 2B). We found that leptin added simultaneously to both the upper and lower chambers of Chemotaxicell showed a migratory effect on human basophils that was comparable to the effect of leptin added only to the lower chambers, indicating that the effect of leptin on human basophils is both chemotactic and chemokinetic (Fig. 2B).

Leptin enhanced survival of human basophils

Leptin has already been shown to enhance the longevity of eosinophil and other inflammatory cells (23, 24, 30, 31). We next examined the effect of leptin on basophil survival. Highly purified basophils cultured for 96 h were analyzed to determine the percentages of live cells and apoptotic cells. As shown in Fig. 3A, leptin showed dose-dependent enhancement of basophil survival. The maximal effect of leptin on human basophil survival was seen at a concentration of 10 μM, but it was slightly weaker than the effect of IL-3, the most potent basophil survival factor. Also, the number of apoptotic basophils decreased with leptin stimulation as the number of live basophils increased (data not shown). Time-course analyses revealed that leptin maintained basophil survival at each time point. These results indicate that leptin is a survival-enhancing factor for human basophils, exerting effects similar to those reported for it on other granulocytes, including eosinophils and neutrophils.

Leptin positively regulates CD63 expression on human basophils

CD63 is expressed on the inner membrane of the cytoplasmic granules of human basophils, and it appears on the cell surface when the inner membrane fuses with the surface membrane at the time of degranulation. Therefore, it is thought that CD63 can be used as a marker of degranulation and activation of human basophils (32). Accordingly, we next studied the effect of leptin on human basophil expression of CD63 (Fig. 4A). IL-3 was used as a control and, consistent with an earlier report (33), it markedly upregulated CD63 expression (Fig. 4). Leptin also enhanced surface CD63 expression by basophils, and surprisingly, at 10 μM, this enhancement was much stronger than that by IL-3 at 100 pM. The effect of leptin was dose-dependent and was maximal at 10 μM. Importantly, the enhancing effect of leptin was neutralized by LepR blockade, as shown in Fig. 4B, indicating that leptin affects basophils through binding to LepR. Also, when we added a neutralizing Ab against leptin, the surface level of CD63 did not change (data not shown), implying that intrinsic leptin does not affect the innate CD63 level on basophils.

We also examined whether leptin affected human basophil surface expression of CD11b, another activation marker for human basophils and often an important adhesion molecule involved in basophil adhesion to the basement membrane and endothelial cells of vessel walls (34, 35). However, leptin showed almost no enhancement of CD11b expression on human basophils (data not shown).

Leptin affects degranulation of human basophils

Next, we tested whether leptin could directly induce degranulation of human basophils. We analyzed basophil degranulation by measuring the amount of histamine released in the supernatant. As a result, leptin at 10 μM directly induced basophil degranulation, although the effect was rather small, accounting for only 10% of total histamine (Fig. 5A). Importantly, leptin enhanced basophil degranulation triggered by CRA-1 Ab. A statistically significant effect was seen with leptin at 10 μM, reaching 10–20% of release enhancement (Fig. 5B). These data indicate that leptin has a small but significant direct effect on basophil degranulation, and that it primes basophils for an enhanced response to aggregation of FcεRI.

Leptin induces Th2 cytokine production by human basophils

One of the most important roles of human basophils is production of IL-4 and IL-13, key Th2 cytokines involved in IgE production and the initiation, formation, and exacerbation of allergic inflammation. Thus, we examined whether leptin affects the production of these cytokines by human basophils. As shown in Fig. 6A, mRNA levels for IL-13 were elevated by leptin. Also, the protein levels of Th2 cytokines, measured by ELISA, were higher in the case of leptin treatment (Fig. 6B), although the effects were


FIGURE 1. Expression of LepR by human basophils. A, cDNAs from highly purified basophils (n = 8), eosinophils (n = 8), neutrophils (n = 4), and PBMCs (n = 4) were tested for LepR by real-time quantitative PCR. The data are expressed as: (copy number of LepR gene/copy number of β-actin gene) $\times$ 100,000. Error bars show the mean quantity for each cell type. B, Surface expression of LepR by human basophils. Highly purified basophils were incubated with either anti-LepR Ab (bold line) or control Ab (shaded area) and then analyzed by flow cytometry. The data are representative of three separate experiments showing similar results. C, Surface expression of LepR by human basophils after overnight incubation. Highly purified basophils were incubated with (bold line) and without (thin line) IL-33 at 100 ng/ml, and then the surface expression of LepR was analyzed by flow cytometry. Shaded area shows basophils stained with control Ab. The data are representative of three separate experiments showing similar results.

FIGURE 2. Leptin induces migration of human basophils. *A*, Twenty thousand Percoll-separated basophils were added to the upper chambers of Chemotaxicell, and the indicated concentrations of chemokines and leptin were added to the lower chambers. The percentages of migrated cells are shown. Error bars represent the SEM ($n = 4$–8). $*p < 0.05$, $***p < 0.001$ versus spontaneous migration in medium alone. *B*, Leptin enhances human basophil migration toward eotaxin. Cells mixed with the indicated concentrations of leptin were added to the upper chambers and then tested for migration toward eotaxin at 10 nM in the lower chambers. The percentages of migrated cells are shown. Error bars represent the SEM ($n = 3$–4). $*p < 0.05$, $***p < 0.001$ versus spontaneous migration in medium alone or corresponding migration toward eotaxin.

smaller than those of IL-3. Collectively, leptin showed a positive influence on Th2 cytokine production by basophils. In contrast, production of Th1 cytokines, specifically IL-2 and IFN-γ, by human basophils was quantified using a Luminex 200 (Luminex, Austin, TX) and Bio-Plex human cytokine assay kits (Bio-Rad Laboratories, Hercules, CA). These cytokines were below the limit of detection, and leptin thus seemed to have no apparent effect on Th1 cytokine production by basophils.

Leptin is expressed in human basophils

It has already been reported that human basophils produce and release leptin (36). To evaluate the capacity of human basophils to synthesize leptin, we performed real-time PCR analysis and ELISA of the basophil culture supernatant. Real-time PCR demonstrated that human basophils expressed mRNA for leptin, as previously reported (36). The expression level did not change in response to IL-33 (100 ng/ml) stimulation (RQ value to the ex-

pression level without stimulation, 0.96 ± 0.77; $n = 4$). In contrast, the concentrations of leptin in the supernatant of basophils cultured in medium alone, or stimulated overnight with IL-3 at 300 pM, IL-33 100 ng/ml, or anti-human IgE Ab at 10 μg/ml, did not reach the lower limit of detection of the ELISA kit (data not shown), indicating that the level of leptin produced by basophils is minimal.

Discussion

Leptin, along with TNF-α, IL-6, and IL-1, is one of the adipokines most abundantly produced by adipocytes that reside in white adipose tissue and whose primary roles are energy storage and regulation (37). Leptin not only acts as an important regulator of body weight but also shows other biological activities relating to hematopoiesis, angiogenesis, and immune responses (22). It is thought that elevated serum levels of leptin in obese individuals may contribute to chronic risk of developing inflammatory conditions (38). Also, there is accumulating evidence that leptin may play various roles in immunomodulation (20, 39). For example, leptin exerts a proliferative effect on CD4$^+$ T cells and also promotes production of proinflammatory Th1 cytokines such as IL-2 and IFN-γ by CD4$^+$ T cells (40–42). It is now widely accepted that cross-talk between inflammatory cells and adipocytes can be mediated by adipokines including leptin, and adipocytes are recog-


FIGURE 3. Leptin maintains viability of human basophils. Highly purified basophils were cultured in medium alone or in the presence of leptin or IL-3 at the indicated concentrations for 96 h. The cells were analyzed by double staining with annexin V and PI. *A*, Live cells were negative for both annexin V and propidium iodide. Data are expressed as percentages of total cell numbers. Error bars represent the SEM ($n = 4$). $**p < 0.01$, $***p < 0.001$ versus medium alone. *B*, Time course of human basophil survival. Highly purified basophils were cultured for the indicated periods of time and the percentages of live cells are shown. Data are representative of four separate experiments showing similar results.


FIGURE 4. Leptin upregulates surface expression of CD63 by human basophils. *A*, Percoll-separated basophils were incubated with medium alone, leptin, or IL-3 at the indicated concentrations for 1 h. Then the surface CD63 expression level was assessed by flow cytometry. The data are expressed as the percentages of MESF values of basophils treated without any stimulus. Error bars represent the SEM ($n = 4$). $*p < 0.05$, $**p < 0.01$, $***p < 0.001$ versus nil. *B*, Percoll-separated basophils were incubated with leptin at 3 μM plus either control goat IgG or anti-LepR neutralizing Ab at 20 μg/ml and then stained for surface CD63 expression. The data are expressed as the percentages of MESF values of basophils treated without any stimulus. Error bars represent the SEM ($n = 3$). $*p < 0.05$.

164

FIGURE 5. Leptin affects basophil degranulation. *A*, Percoll-separated basophils were stimulated with the indicated concentrations of leptin for 45 min, and degranulation was analyzed by measuring the histamine level in the supernatant. The percentage of release was calculated based on the total cellular histamine content. Error bars represent the SEM ($n = 5$). ***$p < 0.001$ versus spontaneous release of histamine in medium alone. *B*, Percoll-separated basophils were incubated with and without leptin at the indicated concentrations for 1 h and then stimulated with CRA-1 mAb at the indicated concentrations. Error bars represent the SEM ($n = 5$). *$p < 0.05$, **$p < 0.01$ versus the corresponding release without leptin pretreatment.

nized to participate in regulating immunological inflammation (43).

Our present study found that human basophils express mRNA for LepR at a level lower than that by PBMCs but similar to neutrophils and eosinophils. Both neutrophils and eosinophils have previously been shown to express LepR, which mediates the actions of leptin (23, 24). Also, freshly isolated basophils clearly expressed LepR protein on their surface. The fact that LepR expression on basophils was upregulated by IL-33, but not by IL-3 or IgE aggregation, seems to be a characteristic of this receptor. It was reported that human basophils express leptin (36), and we have confirmed that these cells express mRNA for leptin. However, their expression of LepR had not been demonstrated until now. Our findings indicate that exogenously added leptin potently affected various aspects of basophil activation, including enhanced migration, survival, CD63 expression, degranulation, and cytokine production, through binding to LepR.

Human basophils usually reside in the bloodstream, and when allergic inflammation is initiated, they migrate and accumulate at the inflammatory sites. We have been investigating the mechanisms that control basophil influx into the sites of inflammation. We previously demonstrated that specific Ags can attract basophils, which then use matrix metalloproteinases to move across the basement membrane (28, 34). Our present study revealed that

leptin is also involved in basophil locomotion. It is noteworthy that the migration-inducing activity of leptin was as strong as those of two other known basophil chemoattractants, RANTES and eotaxin. In addition to its chemotactic effect, leptin showed an enhancing effect on migration toward eotaxin. These results collectively suggest that leptin is one of the most potent chemoattractants for human basophils, possessing both chemotactic and chemokinetic potential.

It has already been reported that leptin acts as a survival factor for eosinophils and neutrophils (23, 24). Our present study found that leptin is also a potent survival-enhancing cytokine for basophils. The fact that leptin attracts human basophils and prolongs their survival in vitro suggests that it may influence the development of allergic inflammation in the lungs, where leptin is known to be highly expressed. Moreover, there is increasing clinical evidence for a distinct role of leptin in airway diseases: the serum leptin level correlates positively with the severity of allergic rhinitis (44), increased leptin expression in the bronchial mucosa of chronic obstructive pulmonary disease patients is associated with airway inflammation and airflow obstruction (45), and serum leptin is elevated in female and child asthmatics (46, 47). These findings, together with our present results, suggest that leptin may act as a cytokine involved in the pathogenesis of airway inflammation by prolonging the lifespan of activated inflammatory cells, including basophils.

We also found intriguing results indicating that leptin strongly activates human basophils. First, the expression level of CD63 on the surface of basophils was strongly upregulated by leptin. CD63 is a membrane protein of the LAMP family, which is involved in vesicle fusion events and has been shown to be associated with release of cellular histamine (32). Our assessment of the amount of histamine released showed that basophil degranulation was greatly upregulated by leptin. Although direct induction of basophil degranulation by leptin was minimal, leptin potently primed basophils for enhanced degranulation in response to IgE or FcεRI aggregation. It has also been reported that splenocytes from histidine decarboxylase-deficient mice, which are deficient in histamine, produced larger amounts of leptin as well as IFN-γ and TNF-α in response to Ag stimulation (48). Collectively with our present data, the evidence suggests that leptin may be deeply involved in histamine homeostasis. In addition to upregulation of basophil degranulation, leptin enhanced Th2 cytokine production by human basophils, whereas it showed no effect on their Th1 cytokine production. Basophils are known to be one of the most


FIGURE 6. Leptin induces production of IL-4 and IL-13 by human basophils. *A*, Highly purified basophils were incubated with leptin at 10 μM or IL-3 at 100 pM for 24 h, and the expression levels of IL-13 mRNA by the cells were analyzed by real-time PCR. Data are expressed as the RQ values to the expression without stimulation. Error bars represent the SEM ($n = 5$). *$p < 0.05$ versus medium alone. *B*, Highly purified basophils (5 × 10^5/ml) were treated with leptin at 10 μM or IL-3 at 100 pM for 24 h, and then IL-4 and IL-13 in the supernatant were measured by ELISA. Error bars represent the SEM ($n = 5-7$). *$p < 0.05$ versus medium alone.

potent cell types secreting IL-4 and IL-13, and our data suggest that leptin will accelerate the initiation of Th2-mediated inflammation by activating basophils to produce IL-4 and IL-13. It is remarkable that leptin may upregulate Th2 responses by enhancing basophil Th2 cytokine production, since leptin has long been thought to promote Th1 responses rather than Th2 responses (40). These results imply the existence of an underlying mechanism whereby leptin induces exacerbation of allergic diseases.

The effect of leptin on human basophil activation seems to occur only at high concentrations. The biological levels of leptin found in venous blood under physiological conditions are usually 1–100 ng/ml. However, leptin serum levels rise up to 400 ng/ml in children with chronic renal failure (49), and high levels of leptin are also found in extremely obese subjects due to leptin resistance (50). Additionally, serum leptin levels >700 ng/ml were reported in obese individuals treated with leptin (51). Therefore, leptin may reach levels in vivo that can induce basophil activation under certain circumstances. It is suspected that leptin levels induced in inflamed tissue sites may be even higher than the levels in serum. Also, the low reactivity of basophils seen in experiments might be due to the relatively low potency of recombinant leptin compared with native leptin because of the difference in its glycosylation pattern (52).

Although we confirmed that human basophils express mRNA for leptin, they did not produce large amount of leptin by themselves. Thus, basophils may not be a major source of leptin, but leptin released by them may contribute to paracrine effects on other inflammatory cell types.

Epidemiologic data indicate that the serum levels of leptin are increased in patients suffering from atopic asthma and IgE-associated atopic eczema (47). Also, obesity increases the prevalence of asthma, worsens asthma control, lowers the quality of life, and increases asthma-related hospitalizations (13, 53). In fact, weight loss in obese asthmatics reduces airway obstruction and results in improved lung function, symptoms, morbidity, and health status (16). Our results suggest that the link between obesity and allergic inflammation may be due, at least in part, to leptin-mediated cross-talk between adipocytes and basophils. Besides its potent effects on basophils, leptin shows pleiotropic effects on various types of inflammation, including Th2-mediated reactions. Leptin promotes proliferation of human monocytes (54) and NK cells (55) and their production of inflammatory cytokines protects neutrophils and eosinophils from apoptosis (23, 24) and promotes T cell activation (39). Also, leptin is reported to negatively modulate regulatory T cell proliferation and function (56, 57), which may lead to increased severity of inflammation due to decreased immunological tolerance. In summary, at the sites of allergic inflammation observed in asthma, leptin may act as a potentially important mediator capable of perpetuating airway inflammation by attracting, prolonging the survival of, and activating the functions of various inflammatory cells, including human basophils.

Acknowledgments

Disclosures

The authors have no financial conflicts of interest.

References

1. Naclerio, R. M., D. Proud, A. G. Togias, N. F. Adkinson, Jr., D. A. Meyers, A. Kagey-Sobotka, M. Plaut, P. S. Norman, and L. M. Lichtenstein. 1985. Inflammatory mediators in late antigen-induced rhinitis. N. Engl. J. Med. 313: 65–70.
2. Bascom, R., M. Wachs, R. M. Naclerio, U. Pipkorn, S. J. Galli, and L. M. Lichtenstein. 1988. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J. Allergy Clin. Immunol. 81: 580–589.
3. Sokol, C. L., G. M. Barton, A. G. Farr, and R. Medzhitov. 2008. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat. Immunol. 9: 310–318.
4. Denzel, A., U. A. Maus, M. Rodriguez Gomez, C. Moll, M. Niedermeier, C. Winter, R. Maus, S. Hollingshead, D. E. Briles, L. A. Kunz-Schughart, et al. 2008. Basophils enhance immunological memory responses. Nat. Immunol. 9: 733–742.
5. Karasuyama, H., K. Mukai, Y. Tsujimura, and K. Obata. 2009. Newly discovered roles for basophils: a neglected minority gains new respect. Nat. Rev. Immunol. 9: 9–13.
6. Yoshimura-Uchiyama, C., M. Yamaguchi, H. Nagase, T. Fujisawa, C. Ra, K. Matsushima, T. Iwata, T. Igarashi, K. Yamamoto, and K. Hirai. 2003. Comparative effects of basophil-directed growth factors. Biochem. Biophys. Res. Commun. 302: 201–206.
7. Bischoff, S. C., A. L. de Weck, and C. A. Dahinden. 1990. Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a. Proc. Natl. Acad. Sci. USA 87: 6813–6817.
8. Brunner, T., C. H. Heusser, and C. A. Dahinden. 1993. Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J. Exp. Med. 177: 605–611.
9. Suzukawa, M., M. Iikura, R. Koketsu, H. Nagase, C. Tamura, A. Komiya, S. Nakae, K. Matsushima, K. Ohta, K. Yamamoto, and M. Yamaguchi. 2008. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J. Immunol. 181: 5981–5989.
10. Iikura, M., M. Suzukawa, M. Yamaguchi, T. Sekiya, A. Komiya, C. Yoshimura-Uchiyama, H. Nagase, K. Matsushima, K. Yamamoto, and K. Hirai. 2005. 5-Lipoxygenase products regulate basophil functions: 5-Oxo-ETE elicits migration, and leukotriene B₄ induces degranulation. J. Allergy Clin. Immunol. 116: 578–585.
11. Camargo, C. A., Jr., S. T. Weiss, S. Zhang, W. C. Willett, and F. E. Speizer. 1999. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch. Intern. Med. 159: 2582–2588.
12. Castro-Rodríguez, J. A., C. J. Holberg, W. J. Morgan, A. L. Wright, and F. D. Martinez. 2001. Increased incidence of asthmalike symptoms in girls who become overweight or obese during the school years. Am. J. Respir. Crit. Care Med. 163: 1344–1349.
13. Mosen, D. M., M. Schatz, D. J. Magid, and C. A. Camargo, Jr. 2008. The relationship between obesity and asthma severity and control in adults. J. Allergy Clin. Immunol. 122: 507–511.
14. Peters-Golden, M., A. Swern, S. S. Bird, C. M. Hustad, E. Grant, and J. M. Edelman. 2006. Influence of body mass index on the response to asthma controller agents. Eur. Respir. J. 27: 495–503.
15. Sutherland, E. R., E. Goleva, M. Strand, D. A. Beuther, and D. Y. Leung. 2008. Body mass and glucocorticoid response in asthma. Am. J. Respir. Crit. Care Med. 178: 682–687.
16. Stenius-Aarniala, B., T. Poussa, J. Kvarnström, E. L. Grönlund, M. Ylikahri, and P. Mustajoki. 2000. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ 320: 827–832.
17. Shore, S. A., Y. M. Rivera-Sanchez, I. N. Schwartzman, and R. A. Johnston. 2003. Responses to ozone are increased in obese mice. J. Appl. Physiol. 95: 938–945.
18. Goldberg, A. C., F. Goldberg-Eliaschewitz, M. C. Sogayar, J. Genre, and L. V. Rizzo. 2009. Leptin and the immune response: an active player or an innocent bystander? Ann. N. Y. Acad. Sci. 1153: 184–192.
19. Zhang, Y., R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425–432.
20. Faggioni, R., K. R. Feingold, and C. Grunfeld. 2001. Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J. 15: 2565–2571.
21. Tartaglia, L. A., M. Dembski, X. Weng, N. Deng, J. Culpepper, R. Devos, G. J. Richards, L. A. Campfield, F. T. Clark, J. Deeds, et al. 1995. Identification and expression cloning of a leptin receptor, OB-R. Cell 83: 1263–1271.
22. Fantuzzi, G., and R. Faggioni. 2000. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J. Leukoc. Biol. 68: 437–446.
23. Conus, S., A. Bruno, and H. U. Simon. 2005. Leptin is an eosinophil survival factor. J. Allergy Clin. Immunol. 116: 1228–1234.
24. Bruno, A., S. Conus, I. Schmid, and H. U. Simon. 2005. Apoptotic pathways are inhibited by leptin receptor activation in neutrophils. J. Immunol. 174: 8090–8096.
25. Nagase, H., S. Okugawa, Y. Ota, M. Yamaguchi, H. Tomizawa, K. Matsushima, K. Ohta, K. Yamamoto, and K. Hirai. 2003. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J. Immunol. 171: 3977–3982.
26. Suzukawa, M., A. Komiya, C. Yoshimura-Uchiyama, A. Kawakami, R. Koketsu, H. Nagase, M. Iikura, H. Yamada, C. Ra, K. Ohta, et al. 2007. IgE- and FcεRI-mediated enhancement of surface CD69 expression in basophils: role of low-level stimulation. Int. Arch. Allergy Immunol. 143(Suppl 1): 56–59.
27. Suzukawa, M., R. Koketsu, M. Iikura, S. Nakae, K. Matsumoto, H. Nagase, H. Saito, K. Matsushima, K. Ohta, K. Yamamoto, and M. Yamaguchi. 2008.

Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. *Lab. Invest.* 88: 1245–1253.

28. Suzukawa, M., K. Hirai, M. Iikura, H. Nagase, A. Komiya, C. Yoshimura-Uchiyama, H. Yamada, C. Ra, K. Ohta, K. Yamamoto, and M. Yamaguchi. 2005. IgE- and FcεRI-mediated migration of human basophils. *Int. Immunol.* 17: 1249–1255.

29. Shore, S. A., I. N. Schwartzman, M. S. Mellema, L. Flynt, A. Imrich, and R. A. Johnston. 2005. Effect of leptin on allergic airway responses in mice. *J. Allergy Clin. Immunol.* 115: 103–109.

30. Fujita, Y., M. Murakami, Y. Ogawa, H. Masuzaki, M. Tanaka, S. Ozaki, K. Nakao, and T. Mimori. 2002. Leptin inhibits stress-induced apoptosis of T lymphocytes. *Clin. Exp. Immunol.* 128: 21–26.

31. Gainsford, T., T. A. Willson, D. Metcalf, E. Handman, C. McFarlane, A. Ng, N. A. Nicola, W. S. Alexander, and D. J. Hilton. 1996. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. *Proc. Natl. Acad. Sci. USA* 93: 14564–14568.

32. Knol, E. F., F. P. Mul, H. Jansen, J. Calafat, and D. Roos. 1991. Monitoring human basophil activation via CD63 monoclonal antibody 435. *J. Allergy Clin. Immunol.* 88: 328–338.

33. Sainte-Laudy, J., C. Vallon, and J. C. Guerin. 1995. Enhanced human basophil activation and histamine release by IL3 priming: application to sulfite allergy diagnosis. *Inflamm. Res.* 44(Suppl. 1): S3–S4.

34. Suzukawa, M., A. Komiya, M. Iikura, H. Nagase, C. Yoshimura-Uchiyama, H. Yamada, H. Kawasaki, K. Ohta, K. Matsushima, K. Hirai, et al. 2006. Transbasement membrane migration of human basophils: role of matrix metalloproteinase-9. *Int. Immunol.* 18: 1575–1583.

35. Iikura, M., M. Ebisawa, M. Yamaguchi, H. Tachimoto, K. Ohta, K. Yamamoto, and K. Hirai. 2004. Transendothelial migration of human basophils. *J. Immunol.* 173: 5189–5195.

36. Gilmartin, L., C. A. Tarleton, M. Schuyler, B. S. Wilson, and J. M. Oliver. 2008. A comparison of inflammatory mediators released by basophils of asthmatic and control subjects in response to high-affinity IgE receptor aggregation. *Int. Arch. Allergy Immunol.* 145: 182–192.

37. Wellen, K. E., and G. S. Hotamisligil. 2005. Inflammation, stress, and diabetes. *J. Clin. Invest.* 115: 1111–1119.

38. Iikuni, N., Q. L. Lam, L. Lu, G. Matarese, and A. La Cava. 2008. Leptin and Inflammation. *Curr. Immunol. Rev.* 4: 70–79.

39. Matarese, G., C. Mantzoros, and A. La Cava. 2007. Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. *Curr. Pharm. Des.* 13: 3676–3680.

40. Lord, G. M., G. Matarese, J. K. Howard, R. J. Baker, S. R. Bloom, and R. I. Lechler. 1998. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. *Nature* 394: 897–901.

41. Loffreda, S., S. Q. Yang, H. Z. Lin, C. L. Karp, M. L. Brengman, D. J. Wang, A. S. Klein, G. B. Bulkley, C. Bao, P. W. Noble, et al. 1998. Leptin regulates proinflammatory immune responses. *FASEB J.* 12: 57–65.

42. Martín-Romero, C., J. Santos-Alvarez, R. Goberna, and V. Sánchez-Margalet. 2000. Human leptin enhances activation and proliferation of human circulating T lymphocytes. *Cell. Immunol.* 199: 15–24.

43. Fantuzzi, G. 2005. Adipose tissue, adipokines, and inflammation. *J. Allergy Clin. Immunol.* 115: 911–919, quiz 920.

44. Hsueh, K. C., Y. J. Lin, H. C. Lin, and C. Y. Lin. 2010. Serum leptin and adiponectin levels correlate with severity of allergic rhinitis. *Pediatr. Allergy Immunol.* 21: e155–e159.

45. Bruno, A., P. Chanez, G. Chiappara, L. Siena, S. Giammanco, M. Gjomarkaj, G. Bonsignore, J. Bousquet, and A. M. Vignola. 2005. Does leptin play a cytokine-like role within the airways of COPD patients? *Eur. Respir. J.* 26: 398–405.

46. Sood, A., E. S. Ford, and C. A. Camargo, Jr. 2006. Association between leptin and asthma in adults. *Thorax* 61: 300–305.

47. Guler, N., E. Kirerleri, U. Ones, Z. Tamay, N. Salmayenli, and F. Darendeliler. 2004. Leptin: does it have any role in childhood asthma? *J. Allergy Clin. Immunol.* 114: 254–259.

48. Musio, S., B. Gallo, S. Scabeni, M. Lapilla, P. L. Poliani, G. Matarese, H. Ohtsu, S. J. Galli, R. Mantegazza, L. Steinman, and R. Pedotti. 2006. A key regulatory role for histamine in experimental autoimmune encephalomyelitis: disease exacerbation in histidine decarboxylase-deficient mice. *J. Immunol.* 176: 17–26.

49. Daschner, M., B. Tönshoff, W. F. Blum, P. Englaro, A. M. Wingen, F. Schaefer, E. Wühl, W. Rascher, O. Mehls; European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. 1998. Inappropriate elevation of serum leptin levels in children with chronic renal failure. *J. Am. Soc. Nephrol.* 9: 1074–1079.

50. Lahlou, N., K. Clement, J. C. Carel, C. Vaisse, C. Lotton, Y. Le Bihan, A. Basdevant, Y. Lebouc, P. Froguel, M. Roger, and B. Guy-Grand. 2000. Soluble leptin receptor in serum of subjects with complete resistance to leptin: relation to fat mass. *Diabetes* 49: 1347–1352.

51. Fujioka, K., J. Patane, J. Lubina, and D. Lau. 1999. CSF leptin levels after exogenous administration of recombinant methionyl human leptin. *JAMA* 282: 1517–1518.

52. Cohen, S. L., J. L. Halaas, J. M. Friedman, B. T. Chait, L. Bennett, D. Chang, R. Hecht, and F. Collins. 1996. Human leptin characterization. *Nature* 382: 589.

53. Kattan, M., R. Kumar, G. R. Bloomberg, H. E. Mitchell, A. Calatroni, P. J. Gergen, C. M. Kercsmar, C. M. Visness, E. C. Matsui, S. F. Steinbach, et al. 2010. Asthma control, adiposity, and adipokines among inner-city adolescents. *J. Allergy Clin. Immunol.* 125: 584–592.

54. Zarkesh-Esfahani, H., G. Pockley, R. A. Metcalfe, M. Bidlingmaier, Z. Wu, A. Ajami, A. P. Weetman, C. J. Strasburger, and R. J. Ross. 2001. High-dose leptin activates human leukocytes via receptor expression on monocytes. *J. Immunol.* 167: 4593–4599.

55. Zhao, Y., R. Sun, L. You, C. Gao, and Z. Tian. 2003. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. *Biochem. Biophys. Res. Commun.* 300: 247–252.

56. De Rosa, V., C. Procaccini, G. Calì, G. Pirozzi, S. Fontana, S. Zappacosta, A. La Cava, and G. Matarese. 2007. A key role of leptin in the control of regulatory T cell proliferation. *Immunity* 26: 241–255.

57. Matarese, G., C. Procaccini, V. De Rosa, T. L. Horvath, and A. La Cava. 2010. Regulatory T cells in obesity: the leptin connection. *Trends Mol. Med.* 16: 247–256.